T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug AZD4512 enters human trials
Disease control Recruiting nowThis study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for frail lymphoma patients: drug combo shows promise
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug epcoritamab to a standard chemotherapy combination (R-miniCVP) can better control newly diagnosed diffuse large B-cell lymphoma in older or frail patients who cannot take strong chemotherapy. The study will enroll 40 adults an…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Recruiting nowThis phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New injection shows promise for tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC